Highly increased levels of IgE antibodies to vaccine components in children with influenza vaccine–associated anaphylaxis  by Nagao, Mizuho et al.
Food, drug, insect sting allergy, and anaphylaxisHighly increased levels of IgE antibodies to vaccine
components in children with influenza vaccine–
associated anaphylaxisMizuho Nagao, MD, PhD,a Takao Fujisawa, MD, PhD,a Toshiaki Ihara, MD, PhD,b and Yoichiro Kino, MSc, PhDc
Tsu and Kumamoto, JapanBackground: Influenza vaccines produced in embryonated eggs
might pose a risk to patients with egg allergy. However, patients
experiencing influenza vaccine–associated anaphylaxis (IVA) do
not always have egg allergy. In the 2011-2012 season, an
unusually high incidence of IVA was reported in Japan.
Objective: We sought to identify the cause of the increase in
anaphylactic events in 2011-2012 in Japan.
Methods: We collected blood specimens from patients with IVA
from all areas of Japan. We analyzed 19 patients with confirmed
IVA and 25 age-matched control subjects, including 10 with egg
allergy who had no adverse events after corresponding
vaccination. ELISA was used to measure specific IgE levels to
the trivalent vaccines of several manufacturers and
hemagglutinin proteins derived from both egg and cell cultures.
Antigen-induced basophil activation was evaluated by
measuring CD203c expression by means of flow cytometry.
Vaccine excipients were also examined for effects on CD203c
expression.
Results: None of the patients with IVA had severe egg allergy.
Levels of specific IgE antibodies to influenza vaccine antigens,
whole-vaccine products from different manufacturers, and
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http://dx.doi.org/10.1016/j.jaci.2015.08.001egg and cell cultures were significantly increased in patients
with IVA compared with those in control subjects. Influenza
vaccine–induced CD203c expression in basophils was also highly
enhanced in patients with IVA but not in control subjects.
Because IVA was most frequent in patients who received 2-
phenoxyethanol (2-PE)–containing vaccine, the effect of this
preservative on basophil activation was examined, and the
activation was slightly enhanced by 2-PE but not thimerosal.
Conclusions: The 2011-2012 IVA spike in Japan was caused by
specific IgE antibodies to influenza vaccine components.
Excipients could not be implicated, except for a modest effect of
2-PE. (J Allergy Clin Immunol 2016;137:861-7.)
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Anaphylaxis after vaccination is a rare but significant problem
because it can be fatal if not treated promptly. However, it is
sometimes difficult to distinguish anaphylaxis from other adverse
reactions, such as the vagal reflex. Therefore proper diagnosis and
identification of the causative factor are critical for the manage-
ment and prophylaxis of anaphylaxis, as well as the prevention of
unnecessary contraindications and unnecessary treatments
because of an incorrect diagnosis.
Inactivated influenza vaccines are produced by means of
inoculation of influenza strains into embryonated hen eggs. This
means that there is a risk of anaphylaxis caused by contaminating
egg antigens if these vaccines are administered to patients with egg
allergy. However, safe influenza vaccine use, even in pediatric
patients with severe egg allergy, has been reported,1-3 which sug-
gests that severe allergic reactions to egg-based influenza vaccines
are unlikely. The US Advisory Committee on Immunization Prac-
tices recommends that influenza vaccination of patients with se-
vere egg allergy should be performed by a physician with
experience in the recognition and management of severe allergic
conditions based on the fact that occasional cases of anaphylaxis
in patients with egg allergy have been reported.4
Although the egg albumin levels in influenza vaccines should
be less than 10 mg/mL according to the World Health Organiza-
tion standard,5 the level of egg albumin in vaccines produced in
Japan is far less than that standard.6 In the 2011-2012 influenza
season one manufacturer (manufacturer A) in Japan reported a
significant increase in the incidence of influenza vaccine–associ-
ated anaphylaxis (IVA; approximately 1 in 1.4 million doses in
normal years but 1 in 0.4 million doses in 2011), although no fa-
talities were reported. Most of the patients did not have egg al-
lergy contrary to the common belief that contaminating egg861
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The incidence was increased only in the population administered
the vaccine produced by manufacturer A and not vaccines from
other companies. One of the different ingredients in vaccine
A compared with the other vaccines was 2-phenoxyethanol (2-
PE), which is used as a preservative, whereas the others used
thimerosal. We investigated the cause of these IVA cases by
collecting samples from patients from all over Japan and found
highly increased influenza vaccine antigen-specific IgE anti-
bodies and positive basophil activation in the patients with IVA
but not in control subjects.METHODS
Subjects
Study subjects consisted of a patient group and 2 control groups. The
patient group contained 19 children who experienced IVA in the 2011-2012
season (IVA group). Although the patients lived in different areas of Japan, we
contacted the physicians who reported the anaphylactic events and asked them
to collaborate on this study. The physicians then arranged for participation of
the patients in the study. The diagnosis of IVA was confirmed based on the
Brighton Collaboration case definition of anaphylaxis of levels 1 and 2.7
We established 2 control groups comprising patients who had undergone
influenza vaccination with vaccine A in the same year but had no adverse
events. One group consisted of 10 age-matched children with severe egg
allergy whowere intolerant to eggs at the time of participation in the study and
had a history of egg-induced anaphylaxis (egg allergy group [EA group]). The
other group consisted of 15 age-matched children with no egg allergy (no egg
allergy group [N group], Table I). The subjects’ histories of other allergic dis-
eases were confirmed by the attending physicians.
The study protocol was approved by the Ethics Committee of Mie National
Hospital. All samples were collected after written informed consent had been
obtained from the parents.Blood samples
EDTA-containing whole blood was collected from the patients and control
subjects. The samples were divided into 2 parts: 1 for basophil activation
experiments and 1 for obtaining plasma.Measurement of specific IgE antibody levels
Levels of specific IgE to whole influenza vaccines and the key vaccine
components (ie, hemagglutinin proteins) were measured by means of ELISA,
as described below.
The investigated vaccines were 4 inactivated trivalent influenza vaccines
that had been produced by 4 manufacturers for the 2011-2012 season and 1
produced for the 2010-2011 season in Japan. The vaccine that showed an
increased incidence of IVAwas produced bymanufacturer A for the 2011-2012
season. The vaccines for both the 2011-2012 and 2010-2011 seasons contained
hemagglutinin derived from anA/California/7/2009 (H1N1)pdm–like virus, an
A/Victoria/210/2009 (H3N2)–like virus and a B/Brisbane/60/2008-like (Vic-
toria lineage) virus, and the corresponding hemagglutinin proteins were
separately used as antigens in the assay. In addition to the above hemagglutinin
proteins that were produced in embryonated hen eggs, cell culture–derivedhemagglutinin proteins devoid of egg protein (Kaketsuken, Kumamoto, Japan)
were also used. Other vaccine ingredients, such as preservatives and excipients,
namely formaldehyde, phenoxyethanol, and thimerosal, were also tested as
antigens. All antigens were dissolved (0.1 mg/mL) in carbonate buffer and
placed (0.1 mL per well) in wells of the Nunc-Immuno Plate I (Nunc A_S,
Roskilde, Denmark) for 1.5 hours at room temperature. After removal of the
supernatants, SuperBlock (Pierce, Rockford, Ill) blocking buffer in PBS was
added at 0.15 mL per well and incubated overnight at 48C. Each well was then
washed with PBS-Tween at 0.2 mL per well, and plasma diluted with
SuperBlock blocking buffer (1:5) was added at 0.1 mL per well. The plates
were incubated overnight at room temperature. After washing with PBS-
Tween, biotin-conjugated goat anti-human IgE (1:1,000, 0.1 mL per well;
Vector Laboratories, Burlingame, Calif) was added and incubated for 1 hour at
room temperature. The plates were washed well, and then streptavidin–
horseradish peroxidase (1:5000, 0.1 mL per well; Southern Biotechnology,
Birmingham, Ala) was added and incubated for 1 hour at room temperature.
The plates were washed well and incubated with a substrate, tetramethylbenzi-
dine solution (ICN Biomedicals, Aurora, Ohio), at 0.1 mL per well for
30 minutes under a light shield. The reaction was stopped by adding 1 NHCl at
0.1 mL per well, and the absorbance at 450 nm was measured with LS-PLATE
Manager 2001 (Wako, Osaka, Japan).
Plasma specimens from the 3 patients with anaphylaxis with the highest
absorbance measurements were pooled and used as a positive control. Cord
blood plasma, which did not contain umbilical IgE, was used as a negative
control. A titration curve preparedwith the serially diluted and pooled positive
plasma was used for quantification of specific IgE levels of the samples with
arbitrary units (units per milliliter).Measurement of CD203c expression on basophils
A commercial kit (Allergenicity Kit; Beckman Coulter, Fullerton, Calif)
was used for quantification of basophil CD203c expression. The test was
performed according to the manufacturer’s instructions. Briefly, EDTA-
containing whole blood was incubated with the vaccines and vaccine
components at various concentrations for 60 minutes after addition of a
sufficient amount of calcium solution to neutralize the chelating capacity of
EDTA. Anti-human IgE antibody at 4 mg/mL and PBS served as positive and
negative controls, respectively. PC7-conjugated anti-CD3, fluorescein iso-
thiocyanate–conjugated anti–chemoattractant receptor-homologous molecule
express on TH2 lymphocytes (CRTH2), and phycoerythrin-conjugated anti-
CD203c antibodies were added during the reaction. The samples were then
analyzed on an FC500 flow cytometer (Beckman Coulter). Basophils were de-
tected on the basis of forward side scatter characteristics and negativeCD3 and
positive CRTH2 results. Upregulation of CD203c on basophils was deter-
mined by using a threshold that was defined by the fluorescence of unstimu-
lated cells (negative control) and expressed as the CD203chigh percentage.Statistics
Differences in numeric variables were analyzed with the Mann-WhitneyU
test for unpaired samples and 1-way ANOVA or the Kruskal-Wallis test for
more than 2 independent samples, followed by the Dunn multiple comparison
test. The x2 test was used to examine differences in categorical variables.RESULTS
Demographic data of the subjects
Table I summarizes the background characteristics of the pa-
tients with IVA and the members of the EA and N control groups.
A total of 36 pediatric cases of IVA were reported in the 2011-
2012 season in Japan, and 19 patients were investigated in this
study. Demographics of the rest of the 17 patients who did not
participate in the study were also shown. There were no differ-
ences in age (in months) or sex among the 4 groups. Egg allergy
was identified in only 21% of the IVA group, and no patients with
FIG 2. Influenza vaccine–specific IgE to vaccines from different manufac-
turers. Influenza vaccine–specific IgE levels were measured by means of
ELISA, as described in the Methods section. Solid triangles indicate sub-
jects in the IVA group, and open circles indicate those in the N group.
The 2011 product from manufacturer A was associated with an increased
incidence of IVA. The IVA and N groups showed no differences in levels
of specific IgE to the different vaccines (Kruskal-Wallis test). Dot plots lined
at 2000 U/mL indicate the values are greater than 2000 U/mL because the
upper limit of the assay was 2000 U/mL.
TABLE I. Baseline characteristics of patients with IVA and 2 groups of control subjects
IVA: Investigated in the study IVA: Not investigated P value* EA group N group P valuey
No. 19 17 10 15
Age (y), mean 6 SD 4.7 6 1.5 5.0 6 2.5 y .7856 5.7 6 2.0 4.8 6 2.9 .4886§
Range (y) 2-8 1-9 3-10 0-13
Male sex, no. (%) 14 (74) 11 (64.7) .7206k 7 (70) 8 (53) .4401k
Egg allergy, no. (%) 4 (21) 3 (17.6) 1.0000k 10 (100) 0 (0) <.0001k
Atopic dermatitis, no. (%) 2 (11) 0 (0) .4873k 6 (60) 1 (7) .0019k
Asthma, no. (%) 10 (53) 1 (5.9) .0034k 10 (100) 5 (33) .0005k
History of anaphylaxis (any), no. (%) 0 (0) 0 (0) NA 10 (100) 0 (0) <.0001k
Drug allergy, no. (%) 0 (0) 1 (5.9) .4722k 0 (0) 0 (0) NA
Metal allergy, no. (%) 0 (0) 0 (0) NA 0 (0) 0 (0) NA
Latex allergy, no. (%) 0 (0) 0 (0) NA 0 (0) 0 (0) NA
NA, Not applicable.
*P values for comparison of the investigated IVA group and the noninvestigated IVA group.






FIG 1. Influenza vaccine–specific IgE antibody. Bars indicate medians with
interquartile ranges. Levels of influenza vaccine–specific IgE were signifi-
cantly higher in the IVA group than in the N and EA groups. ***P < .005
and ****P < .001, Kruskal-Wallis test, followed by the Dunn multiple com-
parison test. Dot plots lined at 2000 U/mL indicate the values are greater
than 2000 U/mL because the upper limit of the assay was 2000 U/mL.
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tients with IVA had bronchial asthma compared with 100% in
the EA group and 33% in the N group. In general, the EA group
appeared more allergic than the IVA group.Influenza vaccine–specific IgE antibody
Levels of influenza-specific IgEwere significantly higher in the
IVA group than in the N and EA groups (Fig 1). The antigen used
in the ELISA here was the vaccine that showed an increased inci-
dence of IVA (manufacturer A). Vaccine-specific IgE levels in the
IVA and N groups were also measured by using the other vaccine
products for 2011-2012 from 3 other manufacturers (ie, B, C, and
D) and the product for 2010-2011 from manufacturer A. There
were no differences in titers between the products (Fig 2), indi-
cating that the vaccine-specific IgE in the IVA group was specific
not only to manufacturer A’s vaccine but also to all the influenza
vaccines. We then measured specific IgE levels to thehemagglutinin proteins contained in the vaccines (ie, those from
A [H1N1], A [H3N2], and B-like viruses propagated in embryo-
nated eggs [e] and cell culture [c]) and found that the patients with
IVA had high levels of hemagglutinin-specific IgE (Fig 3). Excip-
ients used in the vaccines (ie, formaldehyde, 2-PE, and thimer-
osal) were also used as antigens in the assay, but there was no
IgE binding to them (data not shown).Basophil CD203c expression induced by influenza
vaccine
To further investigate the biological significance of influenza
vaccine–specific IgE, we examined basophil activation by the
vaccines on the basis of CD203c expression. Influenza vaccine–
induced expression of CD203cwas significantly higher in the IVA
group than in the N and EA groups (Fig 4).
2-PE, which was used as a preservative, was the major different
ingredient in manufacturer A’s vaccine compared with the others.
Thimerosal was used as the preservative by manufacturers B, C,
and D. On the basis of the above ELISA results that there was no
direct IgE-binding activity for the preservatives, we tested the
FIG 3. Hemagglutinin protein-specific IgE titers. Hemagglutinin-specific IgE
levels were measured by means of ELISA, as described in the Methods
section. The antigens used in the assay were embryonated hen egg–
derived hemagglutinin proteins abbreviated as A (H1N1)-e, A (H3N2)-e, and
B-e (A) and cell culture–derived hemagglutinin proteins abbreviated as
A (H1N1)-c, A (H3N2)-c, and B-c (B). Solid triangles indicate subjects in
the IVA group, and open circles indicate those in the N group. Differences
between the IVA and N groups were analyzed by using the Kruskal-Wallis
test. P values are shown at the bottom of each graph. Dot plots lined at
2000 U/mL indicate the values are greater than 2000 U/mL because the up-
per limit of the assay was 2000 U/mL.
**
****
FIG 4. Basophil CD203c expression induced by influenza vaccine. Periph-
eral blood from the subjects was incubated with the influenza vaccine of
manufacturer A at a dilution of 1:333. Bars indicate medians with interquar-
tile ranges. Levels of influenza vaccine–induced expression of CD203c in ba-
sophils were significantly higher in the IVA group than in the N and EA
groups. **P < .01 and ****P < .001, Kruskal-Wallis test, followed by the
Dunn multiple comparison test.
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levels of CD203c. We used vaccine devoid of both preservatives
and added them at the same concentration as the final product.
This experiment was planned and performed after the initial
basophil activation experiments shown in Fig 4. For that reason,
we considered the possibility that basophil reactivity to these an-
tigens might already have decreased if blood sampling was per-
formed too long after the anaphylactic event, and we selected 8
cases for whom less than 3 months had passed since the event.
Thimerosal showed no effect on basophil activation (data not
shown), whereas 2-PE significantly enhanced CD203c expression
in the higher vaccine dilutions of 1:1000 and 1:3333 (Fig 5).Influenza vaccination of 2011-2012 patients with
IVA in the 2012-2013 season
One contraindication for influenza vaccination is a history of
anaphylaxis caused by any component of the vaccine. However, if
influenza vaccine that does not contain phenoxyethanol might be
safe, patients can avoid an ‘‘unnecessary’’ contraindication and be
eligible for vaccination. With approval from the ethics committee
and informed consent from the patients, we vaccinated 3 of the
patients with IVA in the 2012-2013 season with manufacturer A’s
2012-2013 vaccine, which contained thimerosal rather than 2-PE,
for 2 vaccines andmanufacturer B’s vaccine for the third. None of
those patients experienced anaphylaxis, but 2 experienced rather
extensive local swelling. One of those patients was not admin-
istered the second vaccination. The second underwent the second
vaccination after premedication with a nonsedating antihista-
mine, which resulted in reduced swelling. The third patient had a
mild cough after the first vaccination, which resolved spontane-
ously without treatment. He showed no symptoms after the
second vaccination (Table II).DISCUSSION
After a spike in IVA in 2011 in Japan, we promptly collected
blood samples from patients in collaboration with the vaccine
manufacturer and attending physicians in all areas of Japan. Our
aim was to determine the cause of the increase in this life-
threatening event. We were able to enroll 19 of the patients who
had experienced this rare allergic event in 2011. Because IVA has
been known to be related to severe egg allergy, we recruited 2
groups of age-matched control subjects who had been adminis-
tered the same vaccine safely in the 2011 season: one group had
severe egg allergy and the other group had no egg allergy. We
found that the patients with IVA had increased levels of IgE
antibodies to the influenza vaccine components, and their
basophils were significantly activated by the vaccine. Only 21%
of the patients with IVA had egg allergy, but it was not severe, and
they had no history of anaphylaxis. These findings strongly
suggest that the IVA events were caused by allergy to some
component of the influenza vaccine but not to its egg component.
The egg albumin level of influenza vaccines produced in Japan
is less than 0.8 ng/mL,6 which is much less than the World Health
Organization standard.5 Most inactivated trivalent vaccines
distributed in other countries, such as the United States and
United Kingdom, also contain very low amounts of egg proteins,8
and recent reports stated that the vaccines are safe even for most
patients with severe egg allergy.1-3 However, anaphylaxis after
FIG 5. Effect of 2-PE on influenza vaccine–induced expression of CD203c on basophils from patients with
IVA. Influenza vaccine devoid of 2-PE was serially diluted to the indicated concentrations, and whole blood
from 8 patients with IVA was incubated in the presence and absence of 2-PE at a concentration found in the
vaccine product. CD203c expression was significantly enhanced by 2-PE at vaccine dilutions of 1:1000 and
1:3333. *P < .05. ns, Not significant.
TABLE II. Revaccination of patients with IVA the following year
Patient
no. Age (y) Sex Manufacturer
Adverse events
Systemic Local
1 3 F B None Swelling developed at the injection site a few hours
after vaccination and grew to reach over the elbow on
the following day. The second vaccination was
canceled.
2 4 M A None Swelling spread to the elbow after 5-6 h. The second
vaccination was performed after premedication with
a nonsedating antihistamine, and the swelling was
smaller in size than after the first vaccination.
3 7 M A Mild coughing was observed 30 min after the first
vaccination. This resolved spontaneously within
50 min. No symptoms were observed after the second
vaccination.
None
F, Female; M, male.
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low. Recently, the Vaccine Adverse Event Reporting System in
the United States received reports of 12 cases of allergic reactions
after immunization with an egg-free trivalent recombinant hem-
agglutinin influenza vaccine (RIV3).9 The patients had a history
of allergies (particularly to eggs) or previous reactions to other
influenza vaccines, which probably led to their being adminis-
tered RIV3. All the symptoms reported were immediate-type
symptoms, which is consistent with IgE-mediated reactions.
Direct identification of the symptom-eliciting IgE was not per-
formed.9 In the present study we showed that patients with IVA
had high levels of hemagglutinin-specific IgE, and their basophils
were actually activated by the offending vaccine.
Other vaccine components and excipients have also been
reported as possible causes of anaphylaxis. Gelatin, an excipient,
was once a major cause of anaphylaxis related to measles and
other vaccines.10,11 Although it is still used in a yellow fever vac-
cine, gelatin has been eliminated from other vaccines produced in
Japan, and thus the incidence of gelatin-related anaphylaxis has
been significantly reduced.11 The Sabin vaccine, an oral polio
vaccine, contains cow’s milk protein and was reported to cause
an immediate allergic reaction in children with milk allergy.12Allergic reactions to yeast-derived hepatitis B vaccine13,14 and
allergic reactions against the rubber caps of vaccine vials in pa-
tients with latex allergy15 have also been reported. Influenza vac-
cines do not contain yeast. Our patients with IVA did not report
having latex allergy, and they had not experienced allergic reac-
tions with other vaccines in vials with a rubber cap.
The strengths of our study are that, in spite of the low incidence
of IVA, we were able to recruit a relatively large number of
patients with IVA in the same season, and we were also able to
promptly develop the IgE and basophil activation assays. In Japan
physicians are required to report all adverse events after
vaccination to the government’s Pharmaceuticals and Medical
Devices Agency. The Pharmaceuticals and Medical Devices
Agency then provides vaccine manufacturers the pertinent infor-
mation (without patient identification) so that they can take
measures as quickly as possible. In 2011, manufacturer A realized
that the reports of anaphylaxis with their products were very high,
about 3- to 5-fold the average for other years. Because we had
treated several early cases in our area and had started to
investigate the cause, the company helped us to collect samples
from physicians from all over Japan who had treated some of
those patients with IVA. In the end, more than half of the
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enrolled in this study.
Our study is not the first to investigate IgE antibody to influenza
vaccines and their components, but it is the first detailed study to
demonstrate a strong association between influenza vaccine–
specific IgE and IVA. Smith-Norowitz et al16,17 reported, from the
viewpoint of protective immunity, increased IgE antibody levels
to influenza virus after vaccination and after infection. Their study
cohorts were very small, and they showed no evidence of IgE
function, either protective or allergic. In Canada there was a large
increase in anaphylactic and allergy-like reactions to the AS03-
adjuvanted monovalent pandemic H1N1 vaccine in 2009.18 The
investigators used skin prick tests with full-strength products to
identify IgE-mediated reactions, but only 4% of patients and
3% of control subjects had positive responses. They concluded
that IgE-mediated allergies to the pandemic vaccine were rare
and that the reactions were either coincidental or attributable to
other immunologic reactions to the vaccine.18 We also performed
skin prick tests with full-strength vaccine on 3 of our patients with
IVA and 10 control subjects and found that all the patients with
IVA had positive responses, whereas all the control subjects,
including those with egg allergy, had negative responses. Our
enrolled patients with IVA lived throughout Japan, some remote
from us, and the collaborating physicians could send us blood
samples only after obtaining informed consent. Thus we were
not able to perform skin tests on all the patients, and we have
not presented the findings in the Results section. A major differ-
ence between our study and reports from the United States9 and
Canada18 was the age of the patients. Our patients were mostly
male children around 5 years old, whereas the North American
patients with anaphylaxis were mainly middle-aged women.
The pathogenesis might differ.
It is unclear why only the vaccine product of manufacturer
A and not those of other manufacturers caused an increase in IVA
events compared with average years. Because 2-PE was the only
ingredient different from the other products, we investigated the
effect of 2-PE on influenza vaccine–induced basophil activation
and found that it enhanced the activation in the higher vaccine
dilutions of 1:1000 and 1:3333. 2-PE is thought to be a safe
preservative, and it is commonly used in, for example, cosmetics,
ophthalmic solutions, and foods. Several cases of contact
dermatitis caused by 2-PE have been reported.19-21 However, no
specific IgE antibody was detected.21 Although there is a report
of anaphylaxis caused by 2-PE, the anaphylaxis was induced by
a topical product.22 Use of 2-PE in vaccine products has gradually
increased, replacing thimerosal.23 No previous report of 2-PE in
vaccines as the cause of anaphylaxis have been reported. Here
we show the possibility of enhancement of IgE-mediated reac-
tions by 2-PE in vaccine-sensitized subjects, but there have
been no reports suggesting this with other types of vaccine con-
taining 2-PE. It might be that an adverse interaction between 2-
PE and vaccine components occurs only in the case of influenza
vaccines.
In a separate experiment by manufacturer A on the physico-
chemical properties of the vaccine, it was observed that the
particle sizes of the vaccine components increased slightly during
incubation with 2-PE, raising the possibility that larger particles
might have promoted cross-linking of IgE antibodies (personal
communications). Based on the results of our study and their own
investigations, manufacturer A stopped producing the 2-PE–
containing influenza vaccine and replaced it with a thimerosal-containing vaccine for the 2012-2013 season; the incidence of
anaphylaxis returned to the historical level.
Shortcomings of the present study are that we did not prove a
direct causal relationship between influenza-specific IgE and IVA
and that we did not elucidate the detailed mechanisms underlying
IVA. However, challenge tests cannot be ethically performed. Our
demonstration of influenza vaccine–specific IgE and vaccine-
induced basophil activation in patients with IVA might suffice to
prove the relationship. We also examined lymphocyte prolifera-
tion in response to the vaccine in some of the patients and control
subjects but found no differences between the groups (data not
shown). Our results of screening for IgG antibodies in the
hemagglutinin inhibition test also did not differ between the
patients and control subjects (data not shown). Further investiga-
tion of other possible immunologic mechanisms might be
necessary to understand the pathology of IVA.
In conclusion, for the first time, we clearly demonstrated
significantly increased influenza vaccine–specific IgE and
vaccine-induced basophil activation in patients with IVA who
were included in the IVA spike in 2011-2012 in Japan. The
patients were all children (average age, 62 months), mostly male,
and with no severe egg allergy. It is noteworthy that phenox-
yethanol, which is used as a preservative in the causative influenza
vaccine, might have enhanced the allergic reaction. No other risk
factors were found, andwe believe there is no basis for adding any
new contraindications for influenza vaccination at this point.
However, clinicians need to be alert to the possible presence of
IgE to vaccine components if there is occurrence of a rare
immunologic complication of influenza vaccination.
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